Ann Digest Liver Dis | Volume 1, Issue 1 | Research Article | Open Access
Toru Ishikawa*, Michitaka Imai, Takashi Owaki, Hiroki Sato, Yujiro Nozawa, Tomoe Sano, Akito Iwanaga, Keiichi Seki, Terasu Honma and Toshiaki Yoshida
Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Japan
*Correspondance to: Toru Ishikawa
Fulltext PDFBackground/
Aim: Serum Wisteria floribunda agglutinin positive Mac-2-Binding Protein (M2BPGi) is a noninvasive glycolytion-marker for fibrosis. In this study, we analyzed serial changes of fibrous markers during the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy.
Methods: A total 31 chronic hepatitis C and cirrhotic patients recruited from September 2014 to February 2017 were treated with daclatasvir/asunaprevir therapy for 24 weeks. Serum M2BPGi were measured prior to, at the End of Treatment (EOT) and at 24 weeks after the completion of treatment. We also measured Alpha-Fetoprotein (AFP) levels, serum albumin levels and the Fibrosis-4 (Fib 4) index during the therapy and follow-up period.
Results: Thirty patients (96.7%) achieved Sustained Viral Response (SVR). AFP levels decreased significantly. Serum albumin levels improved significantly during the clinical course. M2BPGi levels and Fib-4 index continuously improved significantly.
Conclusion: Daclatasvir/asunaprevir therapy achieves high SVR rate and improve fibrosis markers such as M2BPGi and Fib-4 index.
Wisteria floribunda agglutinin positive Mac-2-binding protein; Daclatasvir; Asunaprevir; FIB-4 index
Ishikawa T, Imai M, Owaki T, Sato H, Nozawa Y, Sano T, et al. Serum Wisteria floribunda Agglutinin Positive Mac-2 Binding Protein and Fib-4 Index on the Clinical Course of Patients with Chronic Hepatitis C Receiving Daclatasvir/Asunaprevir Therapy. Ann Digest Liver Dis. 2017; 1(1): 1001.